Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Buy" from Brokerages

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $43.40.

DNLI has been the topic of a number of analyst reports. UBS Group cut their price objective on shares of Denali Therapeutics from $70.00 to $32.00 and set a "buy" rating on the stock in a research report on Tuesday. HC Wainwright cut their price objective on shares of Denali Therapeutics from $105.00 to $95.00 and set a "buy" rating on the stock in a research report on Wednesday, February 28th. Wedbush reiterated an "outperform" rating and set a $31.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, February 28th. The Goldman Sachs Group cut their price objective on shares of Denali Therapeutics from $73.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, February 29th. Finally, Citigroup initiated coverage on shares of Denali Therapeutics in a research report on Wednesday, December 13th. They set a "buy" rating and a $32.00 price objective on the stock.

Denali Therapeutics Trading Down 5.2 %

DNLI traded down $1.02 during trading hours on Wednesday, hitting $18.42. The company's stock had a trading volume of 1,246,628 shares, compared to its average volume of 1,161,363. The business's 50-day moving average price is $19.12 and its 200-day moving average price is $19.39. Denali Therapeutics has a 12 month low of $15.45 and a 12 month high of $33.31. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of -17.06 and a beta of 1.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.05). Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the prior year, the firm posted ($0.75) earnings per share. On average, analysts forecast that Denali Therapeutics will post -2.62 earnings per share for the current year.

Insider Activity

In other news, Director Vicki L. Sato sold 1,666 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $18.42, for a total transaction of $30,687.72. Following the completion of the sale, the director now directly owns 123,041 shares of the company's stock, valued at $2,266,415.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Steve E. Krognes sold 2,750 shares of the company's stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $47,547.50. Following the completion of the sale, the director now directly owns 139,841 shares of the company's stock, valued at $2,417,850.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 1,666 shares of the company's stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $18.42, for a total transaction of $30,687.72. Following the completion of the sale, the director now directly owns 123,041 shares of the company's stock, valued at $2,266,415.22. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 110,955 shares of company stock valued at $2,219,019. 7.90% of the stock is currently owned by company insiders.

Institutional Trading of Denali Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Denali Therapeutics by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 10,834,483 shares of the company's stock worth $232,508,000 after acquiring an additional 236,702 shares during the period. BlackRock Inc. lifted its position in shares of Denali Therapeutics by 6.7% during the second quarter. BlackRock Inc. now owns 10,106,275 shares of the company's stock valued at $298,236,000 after buying an additional 631,878 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Denali Therapeutics by 3.6% during the third quarter. Wellington Management Group LLP now owns 7,288,960 shares of the company's stock valued at $150,371,000 after buying an additional 250,784 shares during the last quarter. State Street Corp lifted its position in shares of Denali Therapeutics by 11.8% during the third quarter. State Street Corp now owns 4,192,228 shares of the company's stock valued at $128,659,000 after buying an additional 441,528 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Denali Therapeutics by 4.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,648,888 shares of the company's stock valued at $101,475,000 after buying an additional 170,520 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.